Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugmaker Eli Lilly
With that in mind, let's take a closer look at Lilly's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Indianapolis (1876)|
|Market Cap||$46.7 billion|
|Trailing-12-Month Revenue||$24.3 billion|
|Management||Chairman/CEO John Lechleiter
CFO Derica Rice
|Return on Equity (average, past 3 years)||44.3%|
|Cash/Debt||$6.9 billion / $7.0 billion|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 93% of the 1,389 members who have rated Lilly believe the stock will outperform the S&P 500 going forward.
- Dividend, valuation
- Patens issues are well-known (priced in)
- Litigation risks
- FDA risks
Of course, despite its four-star rating, Lilly may not be your top choice. If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Pfizer. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Better Buy: GlaxoSmithKline plc vs. Eli Lilly
Both big pharma stocks have growth drivers. But both also come with baggage.
Is Eli Lilly and Company a Buy in 2018?
The outlook is complicated for this big pharma stock.
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.